Eli Lilly became the first pharmaceutical company to reach a $1 trillion market valuation, driven largely by demand for its obesity medicines and strong commercial performance across its portfolio. The milestone reflects outsized investor interest in GLP-1 and related metabolic therapies, which have reshaped expectations for drug pricing, sales trajectories and industry valuations. The market move intensifies scrutiny on payer strategies, competitive pipelines and pricing policy as other drugmakers accelerate obesity programs and strategic responses.